EUCTR2008-004707-59-BE进行中（未招募）不适用
A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma - IGF-1R protocol
Cliniques Universitaires Saint Luc-Centre du Cancer0 个研究点目标入组 37 人开始时间: 2008年10月14日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 37
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-recurrent and or metastatic head and neck squamous cell carcinoma not amenable to curative treatment with surgery and/or chemotherapy and/or radiation.
- •-recurrence must be confirmed by anatomopathology(cytology or biopsy)
- •-at least one measurable lesion by MRI or CT-scan
- •-failed or relapsing after first line chemotherapy including a platinum or a taxane-based chemotherapy regimen
- •-patients ineligible for chemotherapy could be included in first line
- •-ECOG performance status 0-2, in stable medical condition
- •-Patients must have an expected survival of at least 3 months
- •-paraffin-embedded tumor tissue available for immunohistochemistery
- •-patients must be over 18 years old and must be able to give written inform consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-non-squamous head and neck cancer
- •-nasopharynx cancer
- •-brain metastases
- •-more than two lines of chemotherapy for palliative treatment(except if chemotherapy was given as a part of a multimodal treatment given with a curative intent)
- •-surgery or irradiation or investigationnal drugs within 4 weeks before study inclusion
- •-prior anti-IGF-1R therapy
- •-other concomitant anti cancer therapy
- •-other uncontrolled illnesses
研究者
相似试验
进行中（未招募）
1 期
A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma - IGF-1R protocolEUCTR2008-004707-59-FRCliniques Universitaires Saint Luc-Centre du Cancer
进行中（未招募）
1 期
A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORSEwing's sarcoma family tumoursMedDRA version: 9.1Level: LLTClassification code 10015562Term: Ewing's sarcoma metastaticEUCTR2007-004486-17-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017138
进行中（未招募）
不适用
A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS - not applicableEwing's sarcoma family tumoursMedDRA version: 9.1Level: LLTClassification code 10015562Term: Ewing's sarcoma metastaticEUCTR2007-004486-17-NLPfizer Inc, 235 East 42nd Street, New York, NY 1001776
进行中（未招募）
1 期
A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORSEUCTR2007-004486-17-GBPfizer Inc, 235 East 42nd Street, New York, NY 10017138
进行中（未招募）
不适用
A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING S SARCOMA FAMILY OF TUMORSPhase 1: Pediatric patients 10-18 years old with relapsed/refractory sarcomas (osteosarcoma, rhabdomyosarcoma, desmoplastic round cell tumors [DSRCT] and ESFT). Phase 2: Patients 10 years old or older with relapsed/refractory ESFT (Ewing s sarcoma, extra-osseous Ewing s sarcoma, Askin s and primitive neuroectodermal tumors [PNET]).MedDRA version: 14.1Level: PTClassification code 10015562Term: Ewing's sarcoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004486-17-ITPFIZER100